Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1681598

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1681598

Biologics Market Size, Share, and Growth Analysis, By Type (Tumor Necrosis Factor Inhibitor, T-cell Inhibitor), By Drug Class, By Therapeutic Application, By Source, By Manufacturing, By Region - Industry Forecast 2025

PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The global biologics market has demonstrated robust growth, driven by advancements in biotechnology and the rising demand for targeted therapies. Biologics, pharmaceutical compounds sourced from living organisms, have shifted the landscape of treatment for chronic conditions, including cancer, autoimmune disorders, and infectious diseases. Their tailored and innovative approaches enhance patient outcomes, positioning biopharmaceuticals as critical components in modern healthcare. Key market growth drivers include the escalating prevalence of chronic diseases, such as diabetes and arthritis, necessitating effective treatment options. However, challenges remain in maintaining the integrity of these biologics throughout the supply chain, influenced by temperature and environmental conditions. The US biologics market is set for sustained growth, indicating promising prospects for biopharmaceuticals in improving quality of life and disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segments Analysis

Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biologics Market

The rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, has significantly spurred the demand for innovative biological therapies. These advanced treatments leverage targeted approaches, distinguishing them from traditional chemical-based medications and enhancing their effectiveness. As a result, the biologics market is experiencing substantial growth, driven by the need for more precise and efficient therapeutic options. This trend reflects a broader shift toward personalized medicine, where tailored treatments not only improve patient outcomes but also foster ongoing advancements in biopharmaceutical research and development, further propelling the market forward.

Restraints in the Biologics Market

The biologics market faces significant challenges due to the intricate and expensive processes involved in the development and production of natural products. The stringent regulatory standards in place can limit both the affordability and accessibility of biologic therapies, ultimately hindering market growth. As companies navigate these challenges, the high costs associated with compliance and manufacturing may deter investment and innovation, which could further stifle advancements in biologic treatments. Consequently, the interplay between regulatory demands and production complexities remains a critical restraint for the biologics market, impacting its overall potential and reach in the healthcare industry.

Market Trends of the Biologics Market

The Biologics market is witnessing a significant shift towards personalized medicine, fundamentally transforming therapeutic approaches. This trend emphasizes the development of biologic therapies tailored to the unique genetic profiles and specific disease characteristics of individual patients, leading to more effective and targeted treatments. As a result, innovation in biological sciences is accelerating, with advancements in areas such as monoclonal antibodies, gene therapies, and regenerative medicine. The growing demand for precision therapies is propelling investments and research in this field, expanding the scope and applications of biologics in managing various diseases, thus positioning the market for robust growth in the coming years.

Product Code: SQMIG35H2127

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Biologics Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Tumor Necrosis Factor (TNF) Inhibitor
  • T-cell Inhibitor
  • Selective Co-stimulation Modulators
  • Interleukin-6 (IL-6) or Interleukin-17 Blocker
  • Interleukin-1 (IL-1) Blocker
  • B-cell Inhibitor

Global Biologics Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • Monoclonal Antibody
  • Recombinant Insulin
  • Vaccine
  • Blood Factor
  • Human Growth Hormone
  • Erythropoietin
  • Fusion Protein
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
    • Cell Therapy
    • Oligonucleotides
    • Others
  • Peptide
  • Botulinum Toxin
  • Others

Global Biologics Market Size by Therapeutic Application & CAGR (2025-2032)

  • Market Overview
  • Oncology
  • Autoimmune/Immunologic Diseases
  • Metabolic Disorders
  • Ophthalmic Diseases
  • Respiratory Disorders
  • Inflammatory Bowel Diseases (IBDs)
  • Neurological Disorders
  • Cardiovascular Diseases (CVDs)
  • Musculoskeletal Disorders (MSDs)
  • Infectious Diseases
  • Others

Global Biologics Market Size by Source & CAGR (2025-2032)

  • Market Overview
  • Microbial
  • Mammalian
  • Others

Global Biologics Market Size by Manufacturing & CAGR (2025-2032)

  • Market Overview
  • Outsourced
  • In-House

Global Biologics Market Size by Drug Type & CAGR (2025-2032)

  • Market Overview
  • Branded Drugs
  • Generic Drugs

Global Biologics Market Size by Mode of Purchase & CAGR (2025-2032)

  • Market Overview
  • Prescription Drugs
  • Over-The-Counter (OTC) Drugs

Global Biologics Market Size by Dosage Form & CAGR (2025-2032)

  • Market Overview
  • Injection
  • Tablets
  • Others

Global Biologics Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Parenteral
  • Oral
  • Others

Global Biologics Market Size by End-Users & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Biologics Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Biologics Market Size & CAGR (2025-2032)

  • North America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
    • US
    • Canada
  • Europe (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Samsung Biologics (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza Group AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • WuXi Biologics (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celltrion, Inc. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols, S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!